---
title: "SCNI.US (SCNI.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SCNI.US/news.md"
symbol: "SCNI.US"
name: "SCNI.US"
parent: "https://longbridge.com/en/quote/SCNI.US.md"
datetime: "2026-03-17T21:56:30.704Z"
locales:
  - [en](https://longbridge.com/en/quote/SCNI.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SCNI.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SCNI.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/SCNI.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/SCNI.US/news.md)


# SCNI.US (SCNI.US) — Related News

### [Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price](https://longbridge.com/en/news/279324931.md)
*2026-03-16T21:04:29.000Z*
### [US stock movement quick report: uniQure surged 42.33%, Turbo Energy SA rose 33.86%, Scinai Immunotherapeutics fell 22.67%](https://longbridge.com/en/news/278306711.md)
*2026-03-09T02:00:27.000Z*
> Current Market Overview of the US Stock Market shows a clear divergence between strong and weak performances, with techn

### [OSE narrows pipeline focus amid Boehringer MASH collaboration retreat](https://longbridge.com/en/news/277660319.md)
*2026-03-03T17:27:07.000Z*
> OSE Therapeutics is shifting its focus to late-stage development of its cancer vaccine, Tedopi, and anti-inflammatory dr

### [Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept | SCNI Stock News](https://longbridge.com/en/news/277486940.md)
*2026-03-02T06:20:00.000Z*
> Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) announced a Second Amendment to its Binding Option Agreement for acquiring

### [OSE Immunotherapeutics Reports Increased Shares and Cash in Liquidity Account](https://longbridge.com/en/news/273114995.md)
*2026-01-20T17:00:11.000Z*